| 标题 |
1330 A phase 2 triplet study of plinabulin/docetaxel/pembrolizumab for metastatic NSCLC immediately after progression on immune-checkpoint-inhibitor alone or in combination: Efficacy and biomarker analysis |
| 网址 | |
| DOI | |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)